Last reviewed 2026-04-23 · How we verify

Tivanisiran sodium ophthalmic solution

Tivanisiran sodium ophthalmic solution is an antisense oligonucleotide that targets the SOD1 gene to reduce the production of superoxide dismutase 1 protein.

Tivanisiran sodium ophthalmic solution is an antisense oligonucleotide that targets the SOD1 gene to reduce the production of superoxide dismutase 1 protein. Used for Treatment of glaucoma.

At a glance

Mechanism of action

By targeting the SOD1 gene, tivanisiran sodium ophthalmic solution aims to reduce the production of superoxide dismutase 1 protein, which is implicated in the pathogenesis of glaucoma. This mechanism is based on the understanding that elevated levels of superoxide dismutase 1 protein contribute to the progression of glaucoma. By reducing the production of this protein, tivanisiran sodium ophthalmic solution may help slow or halt the progression of glaucoma.

Approved indications

• Treatment of glaucoma

Common side effects

• Conjunctival hyperemia
• Eye pain
• Foreign body sensation in the eye

Key clinical trials

• Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome (PHASE3)
• Safety Study of Tivanisiran to Treat Dry Eye (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tivanisiran sodium ophthalmic solution CI brief — competitive landscape report
• Tivanisiran sodium ophthalmic solution updates RSS · CI watch RSS
• Sylentis, S.A. portfolio CI